Low levels of let-7b and -c have been identified in different subtypes of AML [51], and the causal relationship of its deregulated expression in cancer can be supported by evidence suggesting it targets a number of genes involved in the cancer process such as KRAS, TRIM71, nRAS, MYC, and HMGA2 [31]. This evidence concerns the gene KRAS and cancer.